Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus abiraterone versus placebo plus abiraterone in first-line metastatic castration-resistant prostate cancer
NL-OMON45999Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa) comparing Olaparib + abiraterone + prednisone with Placebo + abiraterone + prednisone (2 arms). Primary endpoint: Radiographic progression-free survival. Started Apr 2019; status: active, not recruiting.
02
Drugs
olaparibabirateroneprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON45999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45999.